Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-04-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/4/e004218.full |
| _version_ | 1818268896815218688 |
|---|---|
| author | William L Redmond Annah S Rolig Daniel C Rose Saul Kivimae Werner Rubas Grace Helen McGee |
| author_facet | William L Redmond Annah S Rolig Daniel C Rose Saul Kivimae Werner Rubas Grace Helen McGee |
| author_sort | William L Redmond |
| collection | DOAJ |
| first_indexed | 2024-12-12T20:45:47Z |
| format | Article |
| id | doaj.art-4660056a8ddb4319b639349b8a49a853 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-12T20:45:47Z |
| publishDate | 2022-04-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-4660056a8ddb4319b639349b8a49a8532022-12-22T00:12:34ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-04-0110410.1136/jitc-2021-004218Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RTWilliam L Redmond0Annah S Rolig1Daniel C Rose2Saul Kivimae3Werner Rubas4Grace Helen McGee5Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USAEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USAEarle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USAResearch Biology: Pharmacology, Nektar Therapeutics, San Francisco, California, USAResearch Biology: Pharmacology, Nektar Therapeutics, San Francisco, California, USAEarle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USAhttps://jitc.bmj.com/content/10/4/e004218.full |
| spellingShingle | William L Redmond Annah S Rolig Daniel C Rose Saul Kivimae Werner Rubas Grace Helen McGee Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT Journal for ImmunoTherapy of Cancer |
| title | Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT |
| title_full | Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT |
| title_fullStr | Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT |
| title_full_unstemmed | Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT |
| title_short | Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT |
| title_sort | combining bempegaldesleukin cd122 preferential il 2 pathway agonist and nktr 262 tlr7 8 agonist improves systemic antitumor cd8 t cell cytotoxicity over bempeg rt |
| url | https://jitc.bmj.com/content/10/4/e004218.full |
| work_keys_str_mv | AT williamlredmond combiningbempegaldesleukincd122preferentialil2pathwayagonistandnktr262tlr78agonistimprovessystemicantitumorcd8tcellcytotoxicityoverbempegrt AT annahsrolig combiningbempegaldesleukincd122preferentialil2pathwayagonistandnktr262tlr78agonistimprovessystemicantitumorcd8tcellcytotoxicityoverbempegrt AT danielcrose combiningbempegaldesleukincd122preferentialil2pathwayagonistandnktr262tlr78agonistimprovessystemicantitumorcd8tcellcytotoxicityoverbempegrt AT saulkivimae combiningbempegaldesleukincd122preferentialil2pathwayagonistandnktr262tlr78agonistimprovessystemicantitumorcd8tcellcytotoxicityoverbempegrt AT wernerrubas combiningbempegaldesleukincd122preferentialil2pathwayagonistandnktr262tlr78agonistimprovessystemicantitumorcd8tcellcytotoxicityoverbempegrt AT gracehelenmcgee combiningbempegaldesleukincd122preferentialil2pathwayagonistandnktr262tlr78agonistimprovessystemicantitumorcd8tcellcytotoxicityoverbempegrt |